Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary autologous mononuclear cell infusion after primary PCI for acute myocardial infarction
NL-OMON27593Active, not recruiting
- Sponsor
- Netherlands Heart Institute
- Start
- Jun 2005
- Modality
- Stem Cell Therapies → Cell Therapies, Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of autologous bone marrow-derived mononuclear cell and autologous peripheral blood mononuclear cells in myocardial infarction (MI) (3 arms), sponsored by Netherlands Heart Institute. Primary endpoint: Change in regional myocardial function. Started Jun 2005; status: active, not recruiting.
02
Drugs
autologous bone marrow-derived mononuclear cellautologous peripheral blood mononuclear cells
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON27593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27593.